Navigation Links
Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter 2008 Results
Date:2/27/2009

WALTHAM, Mass., Feb. 27 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Alternext US: ILI) announced today that it will host a conference call and Webcast on Monday, March 9, 2009, at 4:30 p.m. EDT to review the Company's fourth quarter and year end 2008 financial results, and provide an update on recent corporate developments.

To access the live call, dial 877-795-3646 (domestic) or 719-325-4833 (international). The live Webcast and replay access of the teleconference will be available on the Investors section of the Company's Website at http://www.ilgenetics.com.

Interleukin Genetics, Inc. (NYSE Alternext US: ILI), is a healthcare company that specializes in the development of genetic biomarker tests for sale to the emerging personalized health market. The Company is focused on the future of health and medicine. Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and commercialize innovative diagnostic and risk assessment genetic tests. These products could help to improve an individual's understanding of needed lifestyle changes or of therapeutic products that can be used to better manage their health. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. Through its AJG subsidiary, the Company also currently offers an array of Nutraceutical and OTCeuticals(R) products, including Ginkoba(TM), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics and its ongoing programs, please visit www.ilgenetics.com.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
2. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
3. Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss
4. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
5. Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results
6. Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. Interleukin-12 indicates survival prospects for melanoma patients
8. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
9. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
10. T cell immunity enhanced by timing of interleukin-7 therapy
11. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... Researchers can ... so routine. A fresh look at this technique may yield big benefits. Scientists ... reproducibility of experiments in a cell culture laboratory—and lessen the risk of contamination ...
(Date:5/23/2016)... ... May 23, 2016 , ... In light of ... reminds pet owners that intervening at the first sign of their pet overheating ... normal body mechanisms cannot keep the body’s temperature within a safe range. Considered ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Society for Women’s Health ... to move on from that role. , “No one in Washington led the way ... said SWHR Founder Florence Haseltine, MD, PhD. “We offer our deep gratitude to Phyllis ...
(Date:5/23/2016)... ... 2016 , ... Hadley Institute for the Blind and Visually ... or visually impaired, announces the election of Julie S. Tye as its next ... of Trustees retained Morris & Berger, a firm specializing in non-profit executive searches, ...
(Date:5/23/2016)... NY (PRWEB) , ... May 23, 2016 , ... ... the company’s top management team to meet the needs of its recent and ... to drive continued growth and business development across widening market segments. Max joined ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 23, 2016 Gamida Cell, a ... of cancer and orphan genetic diseases, announced today it ... million from the Israel Innovation Authority (formerly the Office ... Economy and Industry. The mission of the Israel Innovation ... industries, including science and technology, while stimulating economic growth. ...
(Date:5/22/2016)... 2016 DS Biopharma (DS) ... anti-inflammatory compound DS102 in chronic obstructive pulmonary disease ... (NASH) patients. Recent DS preclinical data ... tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties ... Company will publish further detail on these findings ...
(Date:5/20/2016)... 2016 - Revenue Forecasts ... Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine ... New Study Reveals Selling Opportunities and Revenue Prospects ... ,What is the future of biologics, especially new ... commercial analysis. Staying ahead in data and knowledge, ...
Breaking Medicine Technology: